
    
      Evaluate the ability of ranolazine to favorably modify thrombogenic, inflammatory, lipogenic,
      oxidative stress and hormonal biomarkers in a relatively short period of time in a group of
      ethnically diverse women with chronic stable angina and metabolic syndrome.
    
  